YM155 (Sepantronium Bromide)

For research use only. Not for use in humans.

目录号：S1130

YM155 (Sepantronium Bromide) Chemical Structure

CAS No. 781661-94-7

YM155 (Sepantronium Bromide)是一种有效的survivin抑制药，通过抑制Survivin启动子活性而发挥作用，在HeLa-SURP-luc 和 CHO-SV40-luc细胞中IC50为0.54 nM；对SV40启动子活性抑制作用不显著，能够轻微抑制Survivin与XIAP相互作用。YM155 在乳腺癌细胞中可下调 survivin 和 XIAP、调节自噬并诱导自噬依赖的DNA损伤。Phase 2。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 918.45	现货
5mg	RMB 568.29	现货
25mg	RMB 2214.29	现货
100mg	RMB 6310.26	现货
200mg	RMB 10401.3	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的YM155 (Sepantronium Bromide)发表文献139篇：

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nat Commun, 2021, 12(1):2877

PubMed: 34001881 ( click the link to review the publication )

Nat Commun, 2021, 12(1):2475

PubMed: 33931637 ( click the link to review the publication )

J Clin Invest, 2021, 131(10)146777

PubMed: 33998604 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2021, 118(11)e2022779118

PubMed: 33836600 ( click the link to review the publication )

Food Funct, 2021, 10.1039/d0fo02243h

PubMed: 33502415 ( click the link to review the publication )

Int J Ophthalmol, 2021, 14(4):489-496

PubMed: 33875937 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5722

PubMed: 33184288 ( click the link to review the publication )

Cancer Res, 2020, 80(17):3480-3491

PubMed: 32641414 ( click the link to review the publication )

Elife, 2020, 26;9:e55487

PubMed: 32452381 ( click the link to review the publication )

Eur J Cancer, 2020, 126:93-103

PubMed: 31927215 ( click the link to review the publication )

Cancers (Basel), 2020, 2;12(3) pii: E577

PubMed: 32131402 ( click the link to review the publication )

Mol Cancer Ther, 2020, 4;molcanther.1166.2020

PubMed: 32499301 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Front Mol Biosci, 2020, 7:566291

PubMed: 33425984 ( click the link to review the publication )

World J Gastroenterol, 2020, 26(32):4786-4801

PubMed: 32921957 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):617

PubMed: 32615946 ( click the link to review the publication )

PLoS One, 2020, 13;15(1):e0226917

PubMed: 31929540 ( click the link to review the publication )

Head Neck, 2020, 42(5):913-923

PubMed: 31925995 ( click the link to review the publication )

Oncol Lett, 2020, 20(4):72

PubMed: 32863905 ( click the link to review the publication )

Cell Cycle, 2020, 1-10

PubMed: 32687433 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12841

PubMed: 31663663 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(10):1985-1998

PubMed: 31300540 ( click the link to review the publication )
Lab Invest, 2019, 99(5):612-624

PubMed: 30664711 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):14375

PubMed: 31591437 ( click the link to review the publication )

Sci Rep, 2019, 9(1):11541

PubMed: 31395901 ( click the link to review the publication )

J Proteome Res, 2019, 18(5):2012-2020

PubMed: 30964684 ( click the link to review the publication )

Ann Transl Med, 2019, 7(14):316

PubMed: 31475186 ( click the link to review the publication )

Prostate, 2019, 79(4):352-362

PubMed: 30499118 ( click the link to review the publication )

PLoS One, 2019, 14(8):e0220860

PubMed: 31393941 ( click the link to review the publication )

Immunity, 2018, 48(6):1183-1194

PubMed: 29802019 ( click the link to review the publication )

Mol Syst Biol, 2018, 14(8):e8238

PubMed: 30104419 ( click the link to review the publication )

Cell Death Discov, 2018, 4:107

PubMed: 30479840 ( click the link to review the publication )

J Transl Med, 2018, 16(1):79

PubMed: 29571296 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(2)

PubMed: 29462944 ( click the link to review the publication )

Biomed Pharmacother, 2018, 107:139-145

PubMed: 30086460 ( click the link to review the publication )

Chem Res Toxicol, 2018, 31(7):612-618

PubMed: 29897742 ( click the link to review the publication )

Toxicol Lett, 2018, 292:55-62

PubMed: 29704545 ( click the link to review the publication )

Onco Targets Ther, 2018,

PubMed: 29872320 ( click the link to review the publication )

Oncol Lett, 2018, 15(3):3779-3789

PubMed: 29467895 ( click the link to review the publication )

Oncotarget, 2018, 9(71):33589-33600

PubMed: 30323901 ( click the link to review the publication )

Oncotarget, 2018, 9(49):29180-29192

PubMed: 30018744 ( click the link to review the publication )

Nat Commun, 2017, 8(1):435

PubMed: 28874669 ( click the link to review the publication )

Small, 2017, 13(27)

PubMed: 28544466 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 44(1):293-302

PubMed: 29132131 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2178-2190

PubMed: 28611106 ( click the link to review the publication )
Biochim Biophys Acta Mol Basis Dis, 2017, 1863(3):663-673

PubMed: 27915033 ( click the link to review the publication )

Stem Cells Transl Med, 2017, 6(2):382-393

PubMed: 28191782 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 28596528 ( click the link to review the publication )

Transl Oncol, 2017, 10(4):546-554

PubMed: 28654818 ( click the link to review the publication )

Mol Cell Biochem, 2017, 429(1-2):91-102

PubMed: 28120212 ( click the link to review the publication )

Bioorg Med Chem Lett, 2017, 27(17):4001-4006

PubMed: 28774426 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Med Sci Monit, 2017, 23:1963-1972

PubMed: 28435150 ( click the link to review the publication )

Oncol Lett, 2017, 14(3):3832-3838

PubMed: 28927154 ( click the link to review the publication )

Anticancer Drugs, 2017, 28(2):142-152

PubMed: 27754993 ( click the link to review the publication )

Anticancer Res, 2017, 37(1):75-80

PubMed: 28011476 ( click the link to review the publication )

J Chemother, 2017, 29(3):179-188

PubMed: 28067150 ( click the link to review the publication )

Oncotarget, 2017, 8(34):57047-57057

PubMed: 28915653 ( click the link to review the publication )

Tumour Biol, 2017, 39(6):1010428317706213

PubMed: 28618939 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29340073 ( click the link to review the publication )

Sci Rep, 2017, 7:40723

PubMed: 28139689 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

Cell Physiol Biochem, 2016, 38(6):2426-37

PubMed: 27287458 ( click the link to review the publication )

Oncogenesis, 2016, 10.1038/oncsis.2016.33

PubMed: 27159675 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Gynecol Oncol, 2016, 141(3):564-569

PubMed: 27079211 ( click the link to review the publication )

Int J Oncol, 2016, 48(5):1847-54

PubMed: 26983495 ( click the link to review the publication )

Photochem Photobiol Sci, 2016, 15(6):812-21

PubMed: 27241169 ( click the link to review the publication )

PLoS One, 2016, 11(4):e0153011

PubMed: 27050416 ( click the link to review the publication )
Biochem Biophys Res Commun, 2016, 471(2):309-14

PubMed: 26855135 ( click the link to review the publication )

Eur Rev Med Pharmacol Sci, 2016, 20(7):1251-7

PubMed: 27097943 ( click the link to review the publication )

Mol Med Rep, 2016, 13(4):3415-22

PubMed: 26957114 ( click the link to review the publication )

Oncotarget, 2016, 7(38):61520-61532

PubMed: 27528031 ( click the link to review the publication )

J Hematol Oncol, 2015, 0.36041666667

PubMed: 25895498 ( click the link to review the publication )

Cancer Lett, 2015, 366(1):44-51

PubMed: 26118775 ( click the link to review the publication )

Cancer Lett, 2015, 366(2):160-72

PubMed: 26123662 ( click the link to review the publication )

Sci Signal, 2015, 8(389):ra80

PubMed: 26268608 ( click the link to review the publication )

Cell Death Dis, 2015,

PubMed: 26018732 ( click the link to review the publication )

Mol Cancer Ther, 2015,

PubMed: 25344582 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):527-43

PubMed: 25454348 ( click the link to review the publication )

Mol Endocrinol, 2015, 29(12):1694-707

PubMed: 26452103 ( click the link to review the publication )

Int J Oncol, 2015, 46(2):841-8

PubMed: 25405645 ( click the link to review the publication )

J Orthop Res, 2015, 10.1002/jor.22819

PubMed: 25640185 ( click the link to review the publication )

Int J Oncol, 2015, 46(2):841-8

PubMed: ( click the link to review the publication )

Oncol Rep, 2015, 34(1):407-14

PubMed: 25955434 ( click the link to review the publication )

Oncol Rep, 2015, 34(2):1074-80

PubMed: 26081496 ( click the link to review the publication )

Biomed Res Int, 2015, 2015:630397

PubMed: 26557682 ( click the link to review the publication )

Leuk Res, 2015, 39(12):1473-9

PubMed: 26547260 ( click the link to review the publication )

Oncol Lett, 2015, 10(3):1627-1631

PubMed: 26622722 ( click the link to review the publication )

Cell Biochem Biophys, 2015, 71(2):587-93

PubMed: ( click the link to review the publication )

Cell Biochem Biophys, 2015, 71(2):587-93

PubMed: 25201484 ( click the link to review the publication )

Clin Exp Hypertens, 2015, 10.3109/10641963.2014.987390

PubMed: 25856227 ( click the link to review the publication )

Int J Clin Exp Med, 2015, 8(10):18032-40

PubMed: 26770398 ( click the link to review the publication )
Oncotarget, 2015, 6(30):28895-910

PubMed: 26336820 ( click the link to review the publication )

Oncotarget, 2015, 6(9):7123-35

PubMed: 25704882 ( click the link to review the publication )

Oncotarget, 2015, 6(15):13119-32

PubMed: 25948791 ( click the link to review the publication )

Oncotarget, 2015, 6(15):13476-86

PubMed: 25974963 ( click the link to review the publication )

Nat Chem Biol, 2014, 10(9):768-73

PubMed: 25064833 ( click the link to review the publication )

Int J Cancer, 2014, 10.1002/ijc.28993

PubMed: 24866585 ( click the link to review the publication )

J Hematol Oncol, 2014, 7(1):62

PubMed: 25139395 ( click the link to review the publication )

Br J Pharmacol, 2014, 172(1):214-34

PubMed: 25220225 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(3):R55

PubMed: 24886669 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1543

PubMed: 25429620 ( click the link to review the publication )

J Dent Res, 2014, 10.1177/0022034514553815

PubMed: 25297117 ( click the link to review the publication )

Biochem Pharmacol, 2014, 89(1):31-42

PubMed: 24560876 ( click the link to review the publication )

Apoptosis, 2014, 19(4):748-58

PubMed: 24370995 ( click the link to review the publication )

World J Gastroentero, 2014, 11644

PubMed: ( click the link to review the publication )

World J Gastroenterol, 2014, 20(45):17049-64

PubMed: 25493017 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2014, 140(10):1705-13

PubMed: 24916171 ( click the link to review the publication )

Oncol Rep, 2014, 31(2):771-80

PubMed: 24297644 ( click the link to review the publication )

J Pharm Biomed Anal, 2014, 92:144-8

PubMed: 24518133 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114051

PubMed: 25485635 ( click the link to review the publication )

Leuk Lymphoma, 2014, 5:1-12

PubMed: 25373508 ( click the link to review the publication )

J Oral Pathol Med, 2014, 10.1111/jop.12248

PubMed: 25212570 ( click the link to review the publication )

J Oral Pathol Med, 2014, 10.1111/jop.12299

PubMed: 25475012 ( click the link to review the publication )

Anticancer Res, 2014, 34(10):5287-94

PubMed: 25275021 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10237-50

PubMed: 25296978 ( click the link to review the publication )
Clin Cancer Res, 2013, 19(20):5591-601

PubMed: 24004671 ( click the link to review the publication )

Cancer Res, 2013, 73(3):1190-200

PubMed: 23204226 ( click the link to review the publication )

Int J Cancer, 2013, 133(10):2341-50

PubMed: 23640782 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e471

PubMed: 23348585 ( click the link to review the publication )

Mol Oncol, 2013, 8(3):469-82

PubMed: 24444656 ( click the link to review the publication )

Int J Biochem Cell Biol, 2013, 45(9):2036-44

PubMed: 23838170 ( click the link to review the publication )

PLoS One, 2013, 8(12):e80703

PubMed: 24324622 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 435(1):52-7

PubMed: 23618862 ( click the link to review the publication )

Pediatr Blood Cancer, 2013, 60(1):35-40

PubMed: 22961763 ( click the link to review the publication )

Leukemia, 2012, 26(4):623-32

PubMed: 21960246 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(2):600-5

PubMed: 22190485 ( click the link to review the publication )

Mol Cancer Ther, 2012, 11(9):1988-98

PubMed: 22723337 ( click the link to review the publication )

BMC Cancer, 2012, 12:619

PubMed: 23267699 ( click the link to review the publication )

Int J Biochem Cell Biol, 2012, 44(1):158-69

PubMed: 22041029 ( click the link to review the publication )

Anticancer Res, 2012, 32(5):1681-8

PubMed: 22593446 ( click the link to review the publication )

Pediatr Neonatol, 2012, 53(3):199-204

PubMed: 22770110 ( click the link to review the publication )

Adv Biosci Biotechnol, 2012, 3(6A):657-664

PubMed: 23355956 ( click the link to review the publication )

Basic Res Cardiol, 2011, 106(6):1207-20

PubMed: 21706383 ( click the link to review the publication )

PLoS One, 2011, 6(8):e21980

PubMed: 21829603 ( click the link to review the publication )

产品安全说明书

Survivin抑制剂选择性比较

生物活性

产品描述

靶点

Survivin ^[1]
(HeLa-SURP-luc, CHO-SV40-luc cells)

0.54 nM

体外研究

YM155 30 μM时对SV40作用效果也不大。在p53缺陷的PC-3和PPC-1 人类HRPC细胞中，通过抑制 survivin基因启动子的转录，YM155显著抑制内源性survivin的表达。相反，YM155 100 nM时对c-IAP2, XIAP, Bcl-2, Bcl-xL, Bad, α-actin,及β-tubulin的蛋白表达仍没抑制效果。YM155作用于人类癌细胞系包括PC-3和PPC-1，使细胞发生凋亡，伴随着caspase-3活性上升。YM155有效抑制人类癌细胞系(突变p53或短小p53) 包括PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5及A375 ，IC50值为2.3到11 nM。^[1]另外，YM155增强NSCLC细胞对γ-射线的敏感性。YM155和γ-射线联用，增强凋亡细胞数和caspase-3活性。 YM155推迟修复放射诱导核DNA断裂的双链。^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Kasumi-1	NWDQWoVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYHiVVFnPzJiaB?=	MnHxSG1UVw>?	MnnuTWM2OD1yLkCwPUDDuSByLkCwNFkh\|ryP	NVTQXHdDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OVk4OzFpPkK1OlU6PzNzPD;hQi=>
M-07e	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlvPO\|IhcA>?	NGPmT5BFVVOR	NEn1SFVKSzVyPUCuNFQxKMLzIECuNFE{KM7:TR?=	M3zQNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW5O\|MyLz5{NU[1PVc{OTxxYU6=
THP-1	NW\lb4NFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVy3NkBp	MUDEUXNQ	NUnrS2hYUUN3ME2wMlA2OSEEsTCwMlAyOyEQvF2=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OUezNUc,OjV4NUm3N\|E9N2F-
CMK	M2rzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MorjO\|IhcA>?	MXvEUXNQ	NXjER4ViUUN3ME2wMlA2OyEEsTCwMlAxQSEQvF2=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OUezNUc,OjV4NUm3N\|E9N2F-
MV4-11	M2LWd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoPHO\|IhcA>?	NXX6XG9UTE2VTx?=	MW\JR\|UxRTBwMEW1JOKyKDBwMEK4JO69VQ>?	NX;YWXN6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OVk4OzFpPkK1OlU6PzNzPD;hQi=>
AML-193	Mm\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnvoO\|IhcA>?	Ml64SG1UVw>?	NHXrW2dKSzVyPUCuOFYzKMLzIECuNFYxKM7:TR?=	NITYSoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PVc{OSd-MkW2OVk4OzF:L3G+
HL-60	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkTHO\|IhcA>?	MlLnSG1UVw>?	MYjJR\|UxRTBwMECxJOKyKDBwMECwNkDPxE1?	NVmzbVRrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OVk4OzFpPkK1OlU6PzNzPD;hQi=>
ML-2	MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnO2O\|IhcA>?	MoSySG1UVw>?	NIL4eXdKSzVyPUCuNFA6KMLzIECuNFAzKM7:TR?=	MmjnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NUm3N\|EoRjJ3NkW5O\|MyRC:jPh?=
OCI/AML3	NYnUU\|VPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkTFO\|IhcA>?	MYTEUXNQ	MnjDTWM2OD1yLkCxNUDDuSByLkCwNkDPxE1?	M3\HeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW5O\|MyLz5{NU[1PVc{OTxxYU6=
HEL	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHrPUog4OiCq	M3jhXmROW09?	MnPnTWM2OD1yLkW1PUDDuSByLkCzPEDPxE1?	NWDxVIF2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OVk4OzFpPkK1OlU6PzNzPD;hQi=>
ME-1	M4XnNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWW3NkBp	MYLEUXNQ	MUHJR\|UxRTBwNki0JOKyKDBwMUe5JO69VQ>?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OUezNUc,OjV4NUm3N\|E9N2F-
THP-1	MkPwRZBweHSxc3nzJGF{e2G7	NULPNI9iOcLizszN	M4rX[lczKGh?	M3fuXWROW09?	M4PZSYlv\HWlZYOgZZBweHSxc3nz	NWPpOYFURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OVk4OzFpPkK1OlU6PzNzPD;hQi=>
M-07e	MVnGeY5kfGmxbjDBd5NigQ>?	NUGwNVFvOOLCk{JCpO69VQ>?	MmHoO\|IhcA>?	NV\JNYI1TE2VTx?=	NIfFbYpqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHN2en[rdnnu	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OUezNUc,OjV4NUm3N\|E9N2F-
THP-1	NVy1XXE6TnWwY4Tpc44hSXO\|YYm=	MVyw5qCUOcLizszN	NIfMVFU4OiCq	Mnz5SG1UVw>?	MX3pcoR2[2W\|IHTve45z\We3bHH0bY9vKG:oIGP1dpZqfmmw	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OUezNUc,OjV4NUm3N\|E9N2F-
CMK	MXTGeY5kfGmxbjDBd5NigQ>?	NWDLcVA6OOLCk{JCpO69VQ>?	NUe3[Fl[PzJiaB?=	Mnq0SG1UVw>?	NFfQOWVqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHN2en[rdnnu	M2i4WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW5O\|MyLz5{NU[1PVc{OTxxYU6=
AML-193	M2r1bWZ2dmO2aX;uJGF{e2G7	NFrxNHYx6oDVMdMg{txO	MUi3NkBp	MoPlSG1UVw>?	M1i0XIlv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gV5Vzfmm4aX6=	NI\LVGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PVc{OSd-MkW2OVk4OzF:L3G+
Kasumi-1	NWe2blV6TnWwY4Tpc44hSXO\|YYm=	M1yzO\|DjiJNzwrFOwG0>	NUTySWJDPzJiaB?=	M3LpO2ROW09?	NW\MZZN4cW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBUfXK4aY\pci=>	M2P3[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW5O\|MyLz5{NU[1PVc{OTxxYU6=
MV4-11	NVLz[ZNITnWwY4Tpc44hSXO\|YYm=	NYfwNZVsOOLCk{JCpO69VQ>?	MY[3NkBp	M{PK[WROW09?	NIX4R2ZqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHN2en[rdnnu	Mn7nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NUm3N\|EoRjJ3NkW5O\|MyRC:jPh?=
MUG-Chor	MlrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHzEVnExNTVizszN	NX\xb4VCOjRxNEigbC=>		Mn23TWM2OD15LkC15qCKdk1iZn;yJFQ5cA>?	M2HodFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkSwNVg2Lz5{NU[0NFE5PTxxYU6=
U-CH1	NIH5c5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;mVo9wOC13IN88US=>	M162dFI1NzR6IHi=		NHTLR4JKSzVyPUmuNFPjiImwTTDmc5IhPDiq	MkTIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NECxPFUoRjJ3NkSwNVg2RC:jPh?=
KATOIII	NUeyN4tuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYCxNE8zOCCwTR?=	NH:xToM1QCCq		NWXLbJIycW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NU\OU\|RnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2N\|UxPTVpPkK1OlM2ODV3PD;hQi=>
AGS	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rK[lExNzJyIH7N	MVW0PEBp		M1\HWIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MkfTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4M{WwOVUoRjJ3NkO1NFU2RC:jPh?=
SACC-83	M2DnXGZ2dmO2aX;uJGF{e2G7	NG\kXJU2KG6P	MWS0PEBp		MnT3[IVkemWjc3XzJI52[2ynYYKg[ZhxemW\|c3nvckBw\iCKSV[tNe6y	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR6NU[zOUc,OjV2OEW2N\|U9N2F-
INA-6	NVW2UmVvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEC5UpIxNTVyMDDuUS=>	NX3L[W13PDhiaB?=		NG\vfGNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MoGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{OU[5O\|goRjJ3Mkm2PVc5RC:jPh?=
U-266	M1fvcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7UNE02ODBibl2=	NIrKRng1QCCq		MXTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NGD1TFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK5Olk4QCd-MkWyPVY6Pzh:L3G+
MOLP-8	NWT1U\|NsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHq4O\|ExNTVyMDDuUS=>	MmXsOFghcA>?		MUHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	M1vCXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mkm2PVc5Lz5{NUK5Olk4QDxxYU6=
HG-1	MoPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MViwMVUxOCCwTR?=	MUm0PEBp		MXXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NFzLfGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK5Olk4QCd-MkWyPVY6Pzh:L3G+
NCI-H929	M1G1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPQNE02ODBibl2=	M2fGTVQ5KGh?		M{XwTIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	M2DhNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mkm2PVc5Lz5{NUK5Olk4QDxxYU6=
OPM-2	MnPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXewMVUxOCCwTR?=	MUK0PEBp		NFrEW\|FqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NYPHOHBpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyPVY6PzhpPkK1Nlk3QTd6PD;hQi=>
L-363	NGnxfIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXzTmN3OC13MECgcm0>	Mn20OFghcA>?		MoLJbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NHjKU4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK5Olk4QCd-MkWyPVY6Pzh:L3G+
MOLP-2	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLXT3hiOC13MECgcm0>	Mnr4OFghcA>?		M1flfYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ7Nkm3PEc,OjV{OU[5O\|g9N2F-
KMS-12-BM	NIHlVJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHPfJZ6OC13MECgcm0>	NED5dVM1QCCq		NUL4U4Z5cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NWXXb5FnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyPVY6PzhpPkK1Nlk3QTd6PD;hQi=>
SK-MM-2	M{Xxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPaXIMxNTVyMDDuUS=>	NGLHd2c1QCCq		NWnsdYc6cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M2LoVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mkm2PVc5Lz5{NUK5Olk4QDxxYU6=
U-266	MWDBdI9xfG:\|aYOgRZN{[Xl?	NWjOR5Q3OC13MDDuUS=>	MkPwNlQhcA>?		Mn;TbY5lfWOnczDhdI9xfG:\|aYO=	NXv5TnBPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyPVY6PzhpPkK1Nlk3QTd6PD;hQi=>
INA-6	MonxRZBweHSxc3nzJGF{e2G7	MVmwMVUxKG6P	M375VVI1KGh?		MkTTbY5lfWOnczDhdI9xfG:\|aYO=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ7Nkm3PEc,OjV{OU[5O\|g9N2F-
MCF7	NU\BTnlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NH[3SnI4OiCq		MXnJR\|UxRTF\|INMxJFYhdk1?	M3\hZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkKwNlI2Lz5{NUKyNFIzPTxxYU6=
MCF7-TamR6	NILYTFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHOxTG04OiCq		MUfJR\|UxRThiwsGgOkBvVQ>?	NVr2cY16RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNlAzOjVpPkK1NlIxOjJ3PD;hQi=>
MCF7-TamR7	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXW3NkBp		MUfJR\|UxRThiwsGgN{BvVQ>?	M4fQclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkKwNlI2Lz5{NUKyNFIzPTxxYU6=
MCF7-TamR8	MorSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4DBVVczKGh?		M4XpNWlEPTB;MUWgxtEhPiCwTR?=	M33RfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkKwNlI2Lz5{NUKyNFIzPTxxYU6=
MCF7-TamC3	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWm3NkBp		NHTiO3RKSzVyPU[gxtEhOyCwTR?=	NGDndZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKyNFIzPSd-MkWyNlAzOjV:L3G+
MCF7-TamC6	NVfRdZVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFPtPHI4OiCq		MkfSTWM2OD14INMxJFAvOSCwTR?=	Mof0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MkCyNlUoRjJ3MkKwNlI2RC:jPh?=
MDA-MB-231	Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWC3NkBp		NGHxOZJKSzVyPUWgxtEhOSCwTR?=	NVzBXmp2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNlAzOjVpPkK1NlIxOjJ3PD;hQi=>
SK-BR-3	MlrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmX0O\|IhcA>?		M2PNb2lEPTB;NzFCtUAxNjNibl2=	NImzdVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKyNFIzPSd-MkWyNlAzOjV:L3G+
Eca109	MV3GeY5kfGmxbjDBd5NigQ>?	NEjrOXoyNTVyIH7N	NF7teHI1QCCq	NIGwUpNFVVOR	M1XWRpN2eHC{ZYPz[ZMhe3W{dnn2bY4h\XiycnXzd4lwdiCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NUWwVoZFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxN\|k{QTVpPkK1NVM6Ozl3PD;hQi=>
TE13	M2HpNWZ2dmO2aX;uJGF{e2G7	NGTUfYIyNTVyIH7N	NUOxT\|duPDhiaB?=	NUPDNlRsTE2VTx?=	NEWxPHd{fXCycnXzd4V{KHO3co\peolvKGW6cILld5Nqd25iaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	M2\iO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUO5N\|k2Lz5{NUGzPVM6PTxxYU6=
Eca109	NFLtdWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVuwMVExOCCwTR?=	NWDhW4d2OjRxNEigbC=>	MYjEUXNQ	NFT3Vpll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	M1XEN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUO5N\|k2Lz5{NUGzPVM6PTxxYU6=
TE13	NXHmcYlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoK3NE0yODBibl2=	M3vETFI1NzR6IHi=	M{XnOGROW09?	MXfk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF\|OUO5OUc,OjVzM{mzPVU9N2F-
MT-3	M3vrc2tqdmG\|ZTDBd5NigQ>?		MVm3NkBp	MonQSG1UVw>?	NWLuNoU3UUN3ME2yMlg3KMLzIECuOVQhdk1iZn;yJGRTPCCneIDy[ZN{cW:w	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh4NkW4OUc,OjR6Nk[1PFU9N2F-
MDA-MB-468	Mor4T4lv[XOnIFHzd4F6		NEfkeJE4OiCq	NXLlfFN{TE2VTx?=	M{DwZWlEPTB;MD6xNUDDuSByLkCxJI5OKG[xcjDEVlQh\XiycnXzd4lwdg>?	M1L6[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OE[2OVg2Lz5{NEi2OlU5PTxxYU6=
SUM-159	M1vYXGtqdmG\|ZTDBd5NigQ>?		M2\SPFczKGh?	MWjEUXNQ	NH;0RnVKSzVyPUGuO\|IhyrFiMD6zN{BvVSCob4KgSHI1KGW6cILld5Nqd25?	Mor0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6Nk[1PFUoRjJ2OE[2OVg2RC:jPh?=
MT-3	MmTHT4lv[XOnIFHzd4F6		Mmi4O\|IhcA>?	M3PBNWROW09?	M4rZO2lEPTB;NUSuNVEhyrFiND6zNkBvVSCob4KgSHI2KGW6cILld5Nqd25?	M3KyPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OE[2OVg2Lz5{NEi2OlU5PTxxYU6=
MDA-MB-468	NIewbYxMcW6jc3WgRZN{[Xl?		NGjjPXY4OiCq	NHfB[XZFVVOR	MU\JR\|UxRTBwMEegxtEhOC5yMjDuUUBnd3JiRGK1JIV5eHKnc4Ppc44>	NIOxfGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi2OlU5PSd-MkS4OlY2QDV:L3G+
SUM-159	Mmm4T4lv[XOnIFHzd4F6		M3zwclczKGh?	MWnEUXNQ	MXXJR\|UxRTZ7LkSgxtEhPC5{MzDuUUBnd3JiRGK1JIV5eHKnc4Ppc44>	M4W0RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OE[2OVg2Lz5{NEi2OlU5PTxxYU6=
MT-3 + NAC	M4rRTmtqdmG\|ZTDBd5NigQ>?		MoraO\|IhcA>?	MX;EUXNQ	NI\GTGtKSzVyPUW2MlIhyrFiMj6wO{BvVSCob4KgSHI2KGW6cILld5Nqd25?	NEf0eYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi2OlU5PSd-MkS4OlY2QDV:L3G+
MT-3 + SB203580	MYXLbY5ie2ViQYPzZZk>		M1PZUVczKGh?	M2To[GROW09?	NHXCS\|NKSzVyPUO4MlQyKMLzIEWuNFIhdk1iZn;yJGRTPSCneIDy[ZN{cW:w	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh4NkW4OUc,OjR6Nk[1PFU9N2F-
DB	Mn7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVexNEBvVQ>?	NXnmSG1LOjRiaB?=	M1n6OWROW09?	Mke2bY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;u	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR6NkW5OUc,OjR2OE[1PVU9N2F-
SU-DHL-8	NWHqOnh7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLBd3MyOTBibl2=	NWTkZpNWOjRiaB?=	MmTrSG1UVw>?	NEjTWVVqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44>	NXG0em5CRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PFY2QTVpPkK0OFg3PTl3PD;hQi=>
WSU-DLCL2	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPpTW9qOTBibl2=	NGTOTIgzPCCq	M3XuemROW09?	NFH6WHZqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44>	M3vZ[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEi2OVk2Lz5{NES4OlU6PTxxYU6=
ACC-2	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX:wMVExOCCwTR?=	NUTweW8yOjRiaB?=		M2TSb4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NWH1NlZRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzO\|A6QTVpPkK0N\|cxQTl3PD;hQi=>
ACC-2	NIDYbYZCeG:ydH;zbZMhSXO\|YYm=	NED6dYcxNTJyIH7N	M2PaNFI1KGh?		MlLlbY5lfWOnczDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN5MEm5OUc,OjR\|N{C5PVU9N2F-
ACC-2	NI\mSlVHfW6ldHnvckBCe3OjeR?=	MmHONE0zOCCwTR?=	NYqwcGQ5OjRiaB?=		M2DkVolv[3KnYYPld{B1cGViY3;ueoVze2mxbjDv[kBNSzOLIITvJGxEO0mL	M1XWSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{ewPVk2Lz5{NEO3NFk6PTxxYU6=
BFTC905	NHOzc4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHjaSXYxNTFyMECgcm0>	NYHwSmY5PDhiaNMg	MlfwSG1UVw>?	NF\icItKSzVyPUKwJI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MlfHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OUe2OFQoRjJ2Mkm3OlQ1RC:jPh?=
T24	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYKwMVExODBibl2=	NHPIfZg1QCCqwrC=	MX\EUXNQ	MULJR\|UxRTJyIH7NMEBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MojpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OUe2OFQoRjJ2Mkm3OlQ1RC:jPh?=
TSGH8301	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfxT4oxNTFyMECgcm0>	NWnzXol7PDhiaNMg	M4PxVmROW09?	Mn[2TWM2OD1{MDDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ7N{[0OEc,OjR{OUe2OFQ9N2F-
BFTC909	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWCwMVExODBibl2=	M1jkUFQ5KGkEoB?=	M2XPdmROW09?	NVzSdGxGUUN3ME2yNEBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NIS2UFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK5O\|Y1PCd-MkSyPVc3PDR:L3G+
BFTC905	M{HaS2Fxd3C2b4Ppd{BCe3OjeR?=	MorNNlAhdk1?	MnKxOFghcA>?	NInKWIVFVVOR	MXPpcoR2[2W\|IHHwc5B1d3Orcx?=	NFToUVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK5O\|Y1PCd-MkSyPVc3PDR:L3G+
BFTC905	NXH3bGRbTnWwY4Tpc44hSXO\|YYm=	NHfi[oYzOCCwTR?=	M1W3dlQ5KGh?	MV7EUXNQ	MkLP[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGxEO0JvSVm=	Ml\ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OUe2OFQoRjJ2Mkm3OlQ1RC:jPh?=
A2780p	NUHKOJRrTnWwY4Tpc44hSXO\|YYm=	MWKwMVExOCCwTR?=	MlGwNlQhcA>?	MnywSG1UVw>?	MonRbY5lfWOnczDTeZJ3cX[rbjDkc5dvemWpdXzheIlwdsLi	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ4Mki3OUc,OjR{NkK4O\|U9N2F-
A2780cis	NVvrO4R6TnWwY4Tpc44hSXO\|YYm=	NELS[XUxNTFyMDDuUS=>	NXnhSZFOOjRiaB?=	NGPOZ\|hFVVOR	MnjZbY5lfWOnczDTeZJ3cX[rbjDkc5dvemWpdXzheIlwdsLi	Mn\5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NkK4O\|UoRjJ2Mk[yPFc2RC:jPh?=
A2780p	NYTFUlNxSXCxcITvd4l{KEG\|c3H5	NYrzbWNbPS1zMECgcm0>	NHezPI8zPC92ODDo	M4HHdGROW09?	MnzFbY5kemWjc3XzJIFxd3C2b4Ppd{BqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=>	NH3QS3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK2Nlg4PSd-MkSyOlI5PzV:L3G+
A2780cis	Mmr2RZBweHSxc3nzJGF{e2G7	M1;tV\|UuOTByIH7N	NF;0[WozPC92ODDo	NYftUWJoTE2VTx?=	NYTQU256cW6lcnXhd4V{KGGyb4D0c5NqeyCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>?	MnriQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NkK4O\|UoRjJ2Mk[yPFc2RC:jPh?=
SH-SY5Y	MYfBdI9xfG:\|aYOgRZN{[Xl?	NEHDOpcyNzFyL{GwNEDDvU1?	NY\vWZRNPzJiaB?=	NFy2SIpFVVOR	M{DQVolv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ3NEW2NEc,OjR{NUS1OlA9N2F-
HL-60	NHnnXnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1rzNVczyqCq	M{Tqe2ROW09?	MlW5TWM2OD1yLkOgcm0>	M1PyV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkG4PFYzLz5{M{[xPFg3OjxxYU6=
U937	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUfBdYo1PzMEoHi=	NFTHWpFFVVOR	MkjITWM2OD1yLkigcm0>	M2DkT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkG4PFYzLz5{M{[xPFg3OjxxYU6=
HL-60	M1PNU2Z2dmO2aX;uJGF{e2G7	Ml;XNeKh\|ryP	MUS2M\|EzNzJ2IHi=	NEPS[GRFVVOR	MUXpcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjDzeZJ3cX[rbh?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzOEi2Nkc,OjN4MUi4OlI9N2F-
U937	NWDmPI5UTnWwY4Tpc44hSXO\|YYm=	NY\WUW46OcLizszN	NUPhSow6Pi9zMj:yOEBp	MWjEUXNQ	M2PkfIlvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJJN2en[rdnnu	NELKflk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xPFg3Oid-MkO2NVg5PjJ:L3G+
HL-60	MoPvRZBweHSxc3nzJGF{e2G7	NV7DPJhkOC5zL{Gg{txO	NHO5Tow5KGh?	M4Kwb2ROW09?	MUnpcoR2[2W\|IHHwc5B1d3Orcx?=	MnfqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUi4OlIoRjJ\|NkG4PFYzRC:jPh?=
Sk-NEP-1	MnX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmGzNU0yODByMDDuUS=>	MkLHNlQhcA>?	NX\reVJ[TE2VTx?=	NH7Cb5RKSzVyPUGwNEBvVQ>?	MlvFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{Nke2PVkoRjJ\|Mk[3Olk6RC:jPh?=
SK-NEP-1	Ml7SRZBweHSxc3nzJGF{e2G7	MX[1NE8yODBibl2=	NF\4OFYyOi9{NDDo	NGfjOnJFVVOR	NWPBbJI6cW6mdXPld{BieG:ydH;zbZM>	NIHtOmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K2O\|Y6QSd-MkOyOlc3QTl:L3G+
TC-32	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVmwMlEuOTByMDDuUS=>			MkDxSWM2OD1\|LkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	M1rFPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OU[xO\|Y{Lz5{Mkm2NVc3OzxxYU6=
TC-71	M3r0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{T5RVAvOS1zMECwJI5O			MYjFR\|UxRTVwNzDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NWm4RVR{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5OlE4PjNpPkKyPVYyPzZ\|PD;hQi=>
SK-ES-1	MmnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPtNE4yNTFyMECgcm0>			MknNSWM2OD1{Lkigcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NHf5SVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mkm2NVc3Oyd-MkK5OlE4PjN:L3G+
RD-ES	NF\xfnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXEb3MxNjFvMUCwNEBvVQ>?			MlPpSWM2OD14LkKgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NIHO[Fg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mkm2NVc3Oyd-MkK5OlE4PjN:L3G+
HEK293	MoLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUGwMlEuOTByMDDuUS=>			MXzFR\|UxRTJ\|LkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl4MUe2N{c,OjJ7NkG3OlM9N2F-
M059J	NHf1XohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY[wMVUxKG6P	NFra[5E1QCCq		MlrzbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NFS2O\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke3NFEyOCd-MkK3O\|AyOTB:L3G+
M059K	MlXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVSwMVUxKG6P	NFjYUHk1QCCq		Ml3pbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NIi4NpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke3NFEyOCd-MkK3O\|AyOTB:L3G+
M059J	M1e3OGFxd3C2b4Ppd{BCe3OjeR?=	M2LNU\|MxKG6P	MkDONlQhcA>?		MmjYbY5lfWOnczDhdI9xfG:\|aYO=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd5MEGxNEc,OjJ5N{CxNVA9N2F-
M059K	MXfBdI9xfG:\|aYOgRZN{[Xl?	Ml7oN\|Ahdk1?	NWLRPHV5OjRiaB?=		MkfvbY5lfWOnczDhdI9xfG:\|aYO=	NIT6bmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke3NFEyOCd-MkK3O\|AyOTB:L3G+
PANC-1	MnjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlriNE4xOS1zMECwJI5O	NVnEPIV6PDhiaB?=		NVjFXFdvUUN3ME2zMlY6KG6P	NH;kS3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkeyN\|g4OSd-MkK3NlM5PzF:L3G+
MIAPaCa-2	M4rXbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1[wNVAvODFvMUCwNEBvVQ>?	Mn7aOFghcA>?		NIHxW\|dKSzVyPUK5MlM3KG6P	M3jkb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{KzPFcyLz5{MkeyN\|g4OTxxYU6=
BxPC-3	M4HkNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnnc3oxNjBzLUGwNFAhdk1?	MYq0PEBp		NVvFWJZbUUN3ME2zNE4zPiCwTR?=	M{XnWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{KzPFcyLz5{MkeyN\|g4OTxxYU6=
PANC-1	M2nobGZ2dmO2aX;uJGF{e2G7	MYGwMVExODBibl2=	MX6yOEBp		MU\pcoR2[2W\|IHTve45z\We3bHH0bY9vKG:oIGjJRXAh[W6mIIP1dpZqfmmwIHX4dJJme3Orb36=	NGnZcZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkeyN\|g4OSd-MkK3NlM5PzF:L3G+
MIAPaCa-2	MULGeY5kfGmxbjDBd5NigQ>?	MoS3NE0yODByIH7N	NFHNOG0zPCCq		M4qzRolv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gXGlCWCCjbnSgd5Vzfmm4aX6g[ZhxemW\|c3nvci=>	M3fJdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{KzPFcyLz5{MkeyN\|g4OTxxYU6=
BxPC-3	NYLRSHNVTnWwY4Tpc44hSXO\|YYm=	NFT0SpoxNTFyMECgcm0>	MVSyOEBp		NVfEWlZ4cW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBZUUGSIHHu[EB{fXK4aY\pckBmgHC{ZYPzbY9v	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd{M{i3NUc,OjJ5MkO4O\|E9N2F-
RPMI-7951	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fUV2dKPTB;Mz6yJI5O	M1zvcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{O3OVAzLz5{MUezO\|UxOjxxYU6=
SK-MEL-5	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;2[YtVT0l3ME20MlIhdk1?	M336fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{O3OVAzLz5{MUezO\|UxOjxxYU6=
A375	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFP0N\|FIUTVyPU[uN{BvVQ>?	M2TQUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{O3OVAzLz5{MUezO\|UxOjxxYU6=
SK-MEL-28	NUPSeIV1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;vRWdKPTB;Nz62JI5O	M3TFZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{O3OVAzLz5{MUezO\|UxOjxxYU6=
SK-MEL-2	NUX6XotQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI[0c\|ZIUTVyPUGxJI5O	M1L6dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{O3OVAzLz5{MUezO\|UxOjxxYU6=
DB	MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVm0POKhcA>?		MnHOS2k2OD1\|LkWgcm0>	NIHWeFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUKzO\|UxQCd-MkGyN\|c2ODh:L3G+
Pfeiffer	NGfpendIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHfiNIE1QMLiaB?=		MmH0S2k2OD1\|Lkmgcm0>	NWHJZ3RyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyN\|c2ODhpPkKxNlM4PTB6PD;hQi=>
SU-DHL-5	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVXlT\|ZtPDkEoHi=		NHTKS41IUTVyPUCuNlMhdk1?	MlLrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{M{e1NFgoRjJzMkO3OVA5RC:jPh?=
SU-DHL-8	NUW5SWJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2W3U\|Q5yqCq		NYfGVolMT0l3ME2xMlQhdk1?	M{[1OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkO3OVA5Lz5{MUKzO\|UxQDxxYU6=
WSU-DLCL-2	NW\BfYdrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHHGWGM1QMLiaB?=		Mn3iS2k2OD1zLkSgcm0>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJ\|N{WwPEc,OjF{M{e1NFg9N2F-
A549	NWfJZ2ROT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				NVXsVphQT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hSTV2OTDj[YxteyxiSVO1NF0xNjBzM{VOwG0>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDhzNEO3OEc,Ojh6MUSzO\|Q9N2F-
DU145	M2H4UGN6fG:2b4jpZ4l1gSCjc4PhfS=>				MULDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{BjgSCPVGSgZZN{[XluIFXDOVA:OC5yMUO4{txO	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDd5NESyOkc,Ojh5N{S0NlY9N2F-
PC3	Ml;hR5l1d3SxeHnjbZR6KGG\|c3H5				NHn5RZBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[nliTWTUJIF{e2G7LDDFR\|UxRTBwMEmy{txO	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDd5NESyOkc,Ojh5N{S0NlY9N2F-
A549	M{S0fGZ2dmO2aX;uJIF{e2G7				NVv6[2ZqUW6qaXLpeIlwdiCxZjDQRWsyKGmwIHj1cYFvKEF3NEmgZ4VtdHNuIFnDOVA:OC53zszN	NFfaOY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEixOFM4PCd-Mki4NVQ{PzR:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Survivin / XIAP / Caspase-7 / Caspase-9 / Caspase-3 / Cleaved Caspase-8 / PARP; PubMed: 26771139 Oncotarget YM155 treatment decreased survivin expression without affecting XIAP and induced cleavage of caspases. Protein expression (caspase-3, -7, -9, -8, PARP) was detected by Western Blot analysis. β-catenin / c-Myc / Cyclin D1 / CD44 ; PubMed: 26771139 Oncotarget YM155 inhibited expression of CSC molecules. SGC-7901 cells were treated with YM155 at indicated doses for 24 hours. The protein levels of genes were determined by Western Blot. p-STAT3 / STAT3 ; PubMed: 22723871 PLoS One Levels of phosphorylated STAT3 and expression of survivin were analyzed by Western blotting after a 24-hours treatment with YM155 and 48 hours after transfection of 40 nM siRNA.	26771139 22723871
Immunofluorescence	EGFR; PubMed: 22723871 PLoS One YM155 (10 nM) induced the nuclear EGFR accumulation. PANC-1 cells were stained with anti-EGFR, anti-Alexa Fluor 488, and DAPI after the YM155 treatment. Scale bars: 10 µm. PARP-1 / PAR ; PubMed: 26090615 Oncotarget A. Nuclear accumulation of active PARP-1 in KYSE410 cells after 12 h of YM155 treatment was evaluated using immunofluorescent analysis. Nuclei were stained with DAPI, as shown in blue. Scale bars: 10 μm. C. Accumulation of the poly-ADP polymer in KYSE410 was evaluated using immunofluorescent analysis after YM155 treatment for 12 h. Nuclei were stained with DAPI, as shown in blue. Scale bars: 10 μm.	22723871 26090615
Growth inhibition assay	Cell viability; PubMed: 29636860 Am J Transl Res Cells were grown in 96-well plates for 24 h and treated with the indicated concentrations of YM155 or docetaxel for 72 h, and cell survival was determined by MTT assay.	29636860

体内研究

YM155按3和10 mg/kg皮下注射前列腺移植瘤，结果显示YM155完全抑制PC-3的肿瘤生长，但是重量没有降低，血细胞数也没有下降。药物动力学分析显示YM155作用于肿瘤组织效果很明显。而且，YM155按5 mg/kg作用于PC-3常位移植瘤时肿瘤抑制率达80% 。^[1]YM155和γ-射线联用作用于携带H460或Calu6 移植瘤的裸鼠，显示出强抗癌活性。^[2]

激酶实验： ^[1]	- 合并启动子-荧光酶素报告实验: 使用Pyrobest聚合酶和引物5’-GCGCGCTCGAGTCTAGACATGCGGATATATTC-3’和5’-GCGCGAA-GCTTTGGCGGTTAATGGCGCGC-3’，从人类基因组DNA中分离2767个碱基对序列的人类survivin基因启动子。在pGL3-Basic质粒的XhoI/HindIII切除位点，内切酶XhoI/HindIII切除产生的PCR片段。产生的质粒称为pSUR-luc。通过DNA测序仪在所有增强序列处测定DNA序列。通过荧光酶素实验，使用短暂转染的HeLa-S3细胞，测定pSUR-luc的活力。使用的pGL3质粒含有SV40启动子和增强子序列。 pSUR-luc和pSV2bsr 质粒通过Lipofectamin2000稳定转染到HeLa细胞中。加入10 μg/mL灭瘟素，根据适当的荧光酶素信号和基因稳定性，筛选HeLa-SURP-luc单一群落。pGL3和pSV2bsr质粒稳定转染到CHO细胞中。加入10 μg/mL灭瘟素，根据适当的荧光酶素信号和基因稳定性，筛选CHO-SV40-luc单一群落。从HeLa-SURP-luc和CHO-SV40-luc群落中获得细胞用于化学筛选。细胞按每孔5×10³接种在96孔板上，加入YM155（溶于DMSO中）。24小时后测定荧光酶素活性。通过回归分析计算IC50值。
细胞实验： ^[1]	- 合并 Cell lines: PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5，和A375细胞 Concentrations: ~ 100 nM Incubation Time: 48小时 Method: PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5，及A375细胞系按5到40×10³密度接种在96孔板上。YM155溶解在DMSO中，持续处理细胞48小时。通过sulforhodamine B试剂测定细胞数。 (Only for Reference)
动物实验： ^[1]	- 合并 Animal Models: 皮下注射PC-3移植瘤的雄性裸鼠(BALB/c nu/nu) Dosages: 5 mg/kg Administration: 皮下注射，每周持续处理3天，处理3周。 (Only for Reference)

参考文献

溶解度 (25°C)

体外	Water	89 mg/mL (200.77 mM)
	DMSO	55 mg/mL (124.07 mM)
	Ethanol	6 mg/mL (13.53 mM)
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： Saline	30 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download YM155 (Sepantronium Bromide) SDF

分子量	443.29
化学式	C₂₀H₁₉BrN₄O₃
CAS号	781661-94-7
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01023386	Completed	Drug: YM155	Cancer	Astellas Pharma Inc	November 2009	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

研究领域

产品类型

定制您的化合物库

YM155 (Sepantronium Bromide)

客户使用Selleck生产的YM155 (Sepantronium Bromide)发表文献139篇：

产品安全说明书

Survivin抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download YM155 (Sepantronium Bromide) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

技术支持

Survivin Signaling Pathway Map

相关Survivin产品